Labcorp Holdings Financials

Labcorp Holdings Inc

LHNYSE

Trade with Public

$317.95

-7.12-2.19%

Últ. Act.: Oct 16, 4:00 PM

$317.95

-7.12-2.19%

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Ganancias: Beneficios de Q3 2026 dentro de 10 días de ahora en mié oct 28th, antes de la apertura del mercado

Fusiones y adquisiciones: OPKO Health (OPK) announced it will sell assets to Labcorp Holdings (LH) on Thursday, October 15, 2026 for $722M paid in cash

Labcorp Holdings Financials

Labcorp Holdings (LH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting

Benzinga Newsdesk

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

Labcorp shares its strategic priorities and reaffirms 2026 guidance at its Investor Day, forecasting steady revenue growth through 2029.

Vandana Singh

PRO
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

Reaffirms full-year 2026 guidanceProvides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%Outlines strategic

Benzinga Newsdesk

PRO
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

Labcorp Holdings (NYSE:LH) affirms FY2026 Adj EPS guidance from $18.10-$18.55 to $18.10-$18.55 vs $18.01 analyst estimate. Affirms FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.710 billion-$14.827

Benzinga Newsdesk

PRO
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 analyst estimate. Raises FY2026 sales outlook from $14.650 billion-$14.800 billion to $14.710 billion-$14.827

Benzinga Newsdesk

PRO
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.99 per share which beat the analyst consensus estimate of $4.78 by 4.39 percent. This is a 14.71 percent increase over earnings of $4.35 per share from the

Benzinga Newsdesk

Labcorp Holdings Inc

Labcorp Holdings Financials

Earnings & Guidance News

PRO
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

PRO
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PRO
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PRO
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PRO
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Labcorp Holdings Financials

Earnings & Guidance News

PRO
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

PRO
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PRO
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PRO
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PRO
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

Labcorp Holdings Inc

Labcorp Holdings Financials

Earnings & Guidance News

PROLabcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

PROLabcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PROLabcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PROLabcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PROLaboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Labcorp Holdings Financials

Earnings & Guidance News

PROLabcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

PROLabcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PROLabcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PROLabcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PROLaboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

PRO
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

PRO
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PRO
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PRO
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PRO
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate

PRO
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

PRO
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR

PRO
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est

PRO
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est

PRO
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate